1. Home
  2. HSTM vs ESPR Comparison

HSTM vs ESPR Comparison

Compare HSTM & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HealthStream Inc.

HSTM

HealthStream Inc.

HOLD

Current Price

$25.24

Market Cap

700.0M

Sector

Technology

ML Signal

HOLD

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.13

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HSTM
ESPR
Founded
1990
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
700.0M
731.9M
IPO Year
1999
2013

Fundamental Metrics

Financial Performance
Metric
HSTM
ESPR
Price
$25.24
$3.13
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$28.00
$8.75
AVG Volume (30 Days)
234.4K
9.9M
Earning Date
05-04-2026
05-07-2026
Dividend Yield
0.66%
N/A
EPS Growth
N/A
60.71
EPS
0.20
N/A
Revenue
$304,064,000.00
$403,135,000.00
Revenue This Year
$9.45
N/A
Revenue Next Year
$5.12
$12.81
P/E Ratio
$126.45
N/A
Revenue Growth
4.26
21.31
52 Week Low
$19.50
$0.95
52 Week High
$29.59
$4.18

Technical Indicators

Market Signals
Indicator
HSTM
ESPR
Relative Strength Index (RSI) 62.52 69.52
Support Level $25.00 $3.11
Resistance Level $26.01 $3.18
Average True Range (ATR) 0.84 0.01
MACD 0.04 -0.03
Stochastic Oscillator 80.84 75.00

Price Performance

Historical Comparison
HSTM
ESPR

About HSTM HealthStream Inc.

HealthStream Inc provides SaaS based applications for healthcare organizations all designed to improve business and clinical outcomes by supporting the people who deliver patient care. The company is focused on helping individuals and organizations in healthcare meet their ongoing learning, clinical development, credentialing, and scheduling needs. It also provides its solutions to nursing schools and nursing students.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: